Sarepta faces another gene therapy hiccup as Regenxbio sues over Jim Wilson's patent

It turns out a regulatory delay isn’t the only bump on Sarepta’s road to gene therapy glory.

The biotech is being sued by Regenxbio, which is alleging that its slate of gene therapy programs, including two for Duchenne muscular dystrophy and limb-girdle muscular dystrophy infringes on a patent originally owned by the University of Pennsylvania.